Reference : Etude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/10051
Etude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection a visee curative du cancer du pancreas: resultats de l'etude randomisee ESPAC-1
French
[en] Clinical Study of the Month. Adjuvant Radio-Chemotherapy and Chemotherapy Following Curative Resection of Pancreatic Cancer: Results of the Randomized Trial Espac-1
Polus, Marc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Jerusalem, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Sautois, Brieuc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Silvestre, R. M. [> > > >]
Collette, M. Y. [> > > >]
Closon, M. T. [> > > >]
Fillet, Georges mailto [Université de Liège - ULg > Département des sciences cliniques > Hématologie - Oncologie médicale]
Feb-2002
Revue Médicale de Liège
57
2
119-22
Yes (verified by ORBi)
0370-629X
[en] The prognosis of pancreatic adenocarcinoma remains poor, with a 5-year survival rate lower than 5%. Resection, the gold standard treatment, can be performed in less than 15% of patients. Following surgery, the median survival is 12 months for the most favourable cancer patients. Adjuvant treatment have attempted to improve results. However, chemotherapy, radiotherapy and multimodal treatments don't have demonstrated a clear advantage in controlled trials. We will discuss results of the current trials in this topic. The randomised trial of the European Study Group for Pancreatic Cancer (ESPAC) recently published in the Lancet revealed a potential benefit of adjuvant chemotherapy. A critical analysis of the publication showed, however, that definitive conclusions of this trial must be interpreted with caution.
http://hdl.handle.net/2268/10051

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
175.pdfPublisher postprint434.84 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.